Crispr Therapeutics (NASDAQ:CRSP) had its price objective upped by Goldman Sachs Group from $52.00 to $75.00 in a note issued to investors on Tuesday, November 19th, The Fly reports. The brokerage currently has a “neutral” rating on the stock. Goldman Sachs Group’s target price suggests a potential upside of 14.75% from the company’s previous close.
CRSP has been the subject of several other research reports. Roth Capital increased their price target on Crispr Therapeutics from $50.00 to $65.00 in a research note on Tuesday, July 30th. William Blair reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Tuesday, July 30th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. BTIG Research raised their target price on Crispr Therapeutics from $51.00 to $59.00 and gave the company a “positive” rating in a research note on Tuesday, July 30th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Crispr Therapeutics in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $69.54.
Shares of NASDAQ CRSP opened at $65.36 on Tuesday. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average price is $58.93 and its two-hundred day moving average price is $48.44.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. As a group, equities research analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of CRSP. Xact Kapitalforvaltning AB acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $207,000. Commonwealth Equity Services LLC increased its holdings in shares of Crispr Therapeutics by 5.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after acquiring an additional 986 shares during the last quarter. Buckley Wealth Management LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $236,000. Carnegie Capital Asset Management LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $1,064,000. Finally, Moody Aldrich Partners LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $1,838,000. 49.82% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is net income?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.